Logo image of HTBX

HEAT BIOLOGICS INC (HTBX) Stock Fundamental Analysis

NYSEARCA:HTBX - NYSE Arca - US42237K4094 - Common Stock

2.38  +0.01 (+0.42%)

Fundamental Rating

2

Taking everything into account, HTBX scores 2 out of 10 in our fundamental rating. HTBX was compared to 551 industry peers in the Biotechnology industry. HTBX has a bad profitability rating. Also its financial health evaluation is rather negative. HTBX is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

HTBX had negative earnings in the past year.
HTBX Yearly Net Income VS EBIT VS OCF VS FCFHTBX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 -10M -20M -30M -40M

1.2 Ratios

Industry RankSector Rank
ROA -28.99%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
HTBX Yearly ROA, ROE, ROICHTBX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 -100 -200 -300 -400

1.3 Margins

HTBX does not have Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) -1658.78%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
HTBX Yearly Profit, Operating, Gross MarginsHTBX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 -1K -2K -3K

More info and screens

3

2. Health

2.1 Basic Checks

Compared to 1 year ago, HTBX has more shares outstanding
Compared to 1 year ago, HTBX has a worse debt to assets ratio.
HTBX Yearly Shares OutstandingHTBX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 5M 10M 15M 20M 25M
HTBX Yearly Total Debt VS Total AssetsHTBX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 20M 40M 60M 80M 100M

2.2 Solvency

An Altman-Z score of 2.71 indicates that HTBX is not a great score, but indicates only limited risk for bankruptcy at the moment.
HTBX has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 2.71
ROIC/WACCN/A
WACCN/A
HTBX Yearly LT Debt VS Equity VS FCFHTBX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 0 50M 100M

2.3 Liquidity

HTBX has a Current Ratio of 21.04. This indicates that HTBX is financially healthy and has no problem in meeting its short term obligations.
HTBX has a Quick Ratio of 21.04. This indicates that HTBX is financially healthy and has no problem in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 21.04
Quick Ratio 21.04
HTBX Yearly Current Assets VS Current LiabilitesHTBX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 20M 40M 60M 80M 100M

More info and screens

5

3. Growth

3.1 Past

HTBX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 9.62%, which is quite good.
HTBX shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -28.09%.
HTBX shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 44.10% yearly.
EPS 1Y (TTM)9.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-2600%
Revenue 1Y (TTM)-28.09%
Revenue growth 3Y-28.54%
Revenue growth 5Y44.1%
Sales Q2Q%2.18%

3.2 Future

HTBX is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -0.56% yearly.
The Revenue is expected to grow by 136.46% on average over the next years. This is a very strong growth
EPS Next Y-23.7%
EPS Next 2Y-3.24%
EPS Next 3Y10.19%
EPS Next 5Y-0.56%
Revenue Next Year128.57%
Revenue Next 2Y55.11%
Revenue Next 3Y129.35%
Revenue Next 5Y136.46%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
HTBX Yearly Revenue VS EstimatesHTBX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 50M 100M
HTBX Yearly EPS VS EstimatesHTBX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 -50 -100 -150

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

HTBX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for HTBX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
HTBX Price Earnings VS Forward Price EarningsHTBX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA 1.04
HTBX Per share dataHTBX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-3.24%
EPS Next 3Y10.19%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for HTBX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

HEAT BIOLOGICS INC

NYSEARCA:HTBX (5/2/2022, 8:04:01 PM)

2.38

+0.01 (+0.42%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-11 2022-03-11/amc
Earnings (Next)05-17 2022-05-17/bmo
Inst Owners1.57%
Inst Owner Change0%
Ins Owners5.77%
Ins Owner Change0%
Market Cap61.05M
Analysts82
Price Target11.6 (387.39%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 28.88
P/FCF N/A
P/OCF N/A
P/B 0.54
P/tB N/A
EV/EBITDA 1.04
EPS(TTM)-1.41
EYN/A
EPS(NY)-1.74
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0.08
BVpS4.41
TBVpSN/A
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -28.99%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) -1658.78%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y0%
ROICexcg growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score0
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 21.04
Quick Ratio 21.04
Altman-Z 2.71
F-Score0
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)9.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-2600%
EPS Next Y-23.7%
EPS Next 2Y-3.24%
EPS Next 3Y10.19%
EPS Next 5Y-0.56%
Revenue 1Y (TTM)-28.09%
Revenue growth 3Y-28.54%
Revenue growth 5Y44.1%
Sales Q2Q%2.18%
Revenue Next Year128.57%
Revenue Next 2Y55.11%
Revenue Next 3Y129.35%
Revenue Next 5Y136.46%
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A